IGC Pharma Inc Stock Price, News & Analysis

IGC Pharma (NYSE American: IGC) will host a mid-year fiscal 2026 shareholder update call on Monday, November 17, 2025 at 11:00 a.m. ET to review operational progress for the quarter and mid-year ended September 30, 2025.

Participants may join by phone using access code 146922 or via live webcast at the provided URL; a replay will be available until February 12, 2026.

IGC Pharma (NYSE:IGC) announced an expansion of its AI-powered in-silico drug discovery platform on November 3, 2025, adding retrosynthetic analysis, molecular docking, toxicology/genotoxic assessment, and predictive bioactivity modeling.

The upgrade aims to accelerate identification and optimization of Alzheimer's candidates by prioritizing compounds in its patent portfolio, predicting target interactions, and flagging toxicity earlier to reduce experimental burden. Ongoing programs noted include IGC-AD1 (Phase 2), TGR-63 (preclinical plaque clearance in cortex and hippocampus), IGC-1C (tau/GLP-1 dual action), and IGC-1A (AI-identified GLP-1 agonist).

IGC Pharma (NYSE American: IGC) announced that its project "AHA: Agentic Harmonization Assistant" was selected as a semi-finalist in the $1 million Alzheimer's Insights AI Prize organized by the Alzheimer's Disease Data Initiative. The company said AHA builds on its MINT-AD deep-learning platform, which integrates clinical, neuroimaging, genetic, lifestyle, cognitive, and genomic data to address data harmonization in Alzheimer’s drug discovery.

The semi-final presentation is scheduled for December 5, 2025 in San Diego, following the CTAD conference. IGC framed the selection as recognition of its AI-driven research capabilities and team execution.

IGC Pharma (NYSE American:IGC) announced expansion of its Phase 2 CALMA trial of investigational IGC-AD1 for agitation in Alzheimer's disease with a new clinical site at the University of South Florida Department of Psychiatry and Behavioral Neurosciences effective October 14, 2025.

Enrollment at the USF site has begun with four participants already enrolled. CALMA is a randomized, double-blind, placebo-controlled Phase 2 study evaluating the efficacy and safety of IGC-AD1; the company says the USF site will help accelerate recruitment and diversify participants as the trial continues to expand across North America.

IGC Pharma (NYSE American: IGC) held its Annual Meeting on October 10, 2025 where stockholders approved all proposals disclosed in the Definitive Proxy on Schedule 14A dated August 18, 2025.

Approved actions include: (i) election of Ram Mukunda and James Moran as Class C directors through the 2028 annual meeting; (ii) ratification of Manohar Chowdhry & Associates as independent registered public accounting firm for fiscal 2026; (iii) authorization to grant 5,000,000 shares of common stock to employees, advisors, directors, and consultants under board/CEO-set metrics; and (iv) amendment to increase authorized common shares from 150,000,000 to 600,000,000.

IGC (NYSE American: IGC) announced preclinical in-vitro data for IGC-1C on October 7, 2025, describing a novel approach that targets tau protein liquid-liquid phase separation (LLPS).

Key findings include inhibition and dissolution of zinc-mediated tau condensates, reduction in condensate size and number, prevention of conversion to amyloid fibrils, and a measured tau binding affinity of Kd 3.95 ± 0.32 μM. IGC-1C was permeable and well tolerated in SH-SY5Y cell cultures. The company plans additional animal validation studies with the stated goal of advancing IGC-1C toward clinical trials.

IGC Pharma (NYSE American: IGC) announced the addition of Ichor Research in Syracuse, New York, as a new clinical trial site for its ongoing Phase 2 CALMA trial. The study evaluates IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease patients.

The trial, designed as a randomized, double-blind, placebo-controlled study, will be led by Principal Investigator Dr. Karl F. Hafner, M.D. at the new site. The CALMA trial aims to assess the safety and efficacy of IGC-AD1 in reducing agitation symptoms, which are among the most common and distressing behavioral symptoms in Alzheimer's patients.

IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its Alzheimer's disease candidate TGR-63. The research reveals TGR-63's dual mechanism of action, demonstrating its ability to target both beta-amyloid (Aβ) plaques and tau protein aggregation, two major hallmarks of Alzheimer's disease.

The studies showed that TGR-63 suppresses tau fibril formation at micromolar concentrations and maintains structural stability under physiological conditions. MALDI mass spectrometry detected the compound in serum samples at both 1- and 24-hours post-administration, indicating strong pharmacological resilience and systemic delivery potential.

IGC Pharma (NYSE American:IGC) has achieved 50% enrollment in its Phase 2 CALMA clinical trial for IGC-AD1, a treatment targeting agitation in Alzheimer's disease. The trial is a multicenter, double-blind, placebo-controlled, randomized study evaluating their proprietary formulation that combines low-dose THC with another active pharmaceutical ingredient.

The company has expanded its trial network to include six new research sites across Florida, Ontario, Rhode Island, Oklahoma, British Columbia, and Puerto Rico. IGC-AD1 shows promise through its multi-modal mechanism of action, potentially addressing both agitation symptoms and disease modification. Based on encouraging Phase 1 data and interim Phase 2 analysis, the company expects to complete the trial in early 2026.